December 26, 2002 - 8:19 a.m.
Gilead Sciences and Triangle Pharmaceuticals Announce Expiration of Hart-Scott-Rodino Waiting Period
Printer Friendly Version 
December 13, 2002 - 9:30 a.m.
Gilead to Receive $300 Million from Offering of Convertible Notes
Printer Friendly Version 
December 12, 2002 - 4:26 p.m.
Gilead to Raise $300 Million From Offering of Convertible Notes
Printer Friendly Version 
December 04, 2002 - 7:30 a.m.
Gilead Sciences to Acquire Triangle Pharmaceuticals for $464 Million
Printer Friendly Version 
November 21, 2002 - 9:12 a.m.
European CPMP Gives Positive Opinion On Hepsera, Gilead's Treatment for Chronic Hepatitis B; Recommendation Granted Eight Months After Filing
Printer Friendly Version 
November 04, 2002 - 8:33 a.m.
New Data Demonstrate Antiviral Activity of Gilead's Hepsera in Patients with Lamivudine-Resistant Chronic Hepatitis B
Printer Friendly Version 
October 31, 2002 - 4:15 p.m.
Gilead Sciences Announces Third Quarter 2002 Financial Results
Printer Friendly Version 
October 28, 2002 - 9:54 a.m.
Gilead Sciences to Release Third Quarter 2002 Financial Results On Thursday, October 31, 2002; Conference Call and Webcast to Follow
Printer Friendly Version 
September 27, 2002 - 3:29 p.m.
Phase III Study of Viread Shows Favorable Lipid and Mitochondrial DNA Profile in Treatment-naive HIV Patients; Data Presented in Late-Breaker Session at 42nd ICAAC
Printer Friendly Version 
September 23, 2002 - 7:32 a.m.
FDA Approves Gilead's Hepsera(TM) for the Treatment of Chronic Hepatitis B
Printer Friendly Version 
August 28, 2002 - 3:41 p.m.
Hepsera Selected as U.S. Trade Name for Adefovir Dipivoxil
Printer Friendly Version 
August 06, 2002 - 8:32 p.m.
FDA Advisory Committee Unanimously Supports Approval of Gilead's Adefovir Dipivoxil to Treat Chronic Hepatitis B
Printer Friendly Version 
August 05, 2002 - 8:57 a.m.
Gilead Announces Posting of FDA Briefing Documents for August 6 Advisory Committee Review of Adefovir Dipivoxil for Chronic Hepatitis B
Printer Friendly Version 
July 24, 2002 - 4:15 p.m.
Gilead Sciences Announces Second Quarter 2002 Financial Results; Strong Viread Sales Push Total Revenues Past $100 Million, Lead to Profitability
Printer Friendly Version 
July 19, 2002 - 4:16 p.m.
Gilead Sciences to Release Second Quarter 2002 Financial Results On Wednesday, July 24, 2002; Conference Call and Webcast to Follow
Printer Friendly Version 
July 11, 2002 - 4:34 a.m.
48-Week Data Demonstrate Ability of Viread to Suppress Viral Load in Patients With Multiple Treatment-Resistant HIV Mutations
Printer Friendly Version 
July 08, 2002 - 1:14 a.m.
48-Week Data Compare Viread to Stavudine When Used as Part of Patients' First Anti-HIV Regimen; Data Presented at XIV International AIDS Conference in Barcelona
Printer Friendly Version 
June 26, 2002 - 8:19 a.m.
Roche Receives Approval in Europe for Tamiflu(R)
Printer Friendly Version 
June 18, 2002 - 4:06 p.m.
Gilead Sciences Announces Acceptance of Viread Late Breaker Abstracts At Upcoming 14th International AIDS Conference
Printer Friendly Version 
June 10, 2002 - 6:58 a.m.
Anadys Forms Collaboration With Gilead to Discover Novel Antiviral Compounds; Anadys' uHTS-ATLAS to be Used to Screen Important and Challenging Viral Target
Printer Friendly Version 
May 21, 2002 - 4:34 p.m.
Webcast Alert: Gilead Sciences, Inc. Announces Its Annual Meeting of Stockholders Conference Call on the Web
Printer Friendly Version 
May 21, 2002 - 4:20 p.m.
Gilead Announces Initiation of NIH-sponsored Phase I Trial to Evaluate Tenofovir Topical Gel as Preventive for Vaginal Transmission of HIV
Printer Friendly Version 
May 07, 2002 - 4:40 p.m.
Gilead Announces Preliminary 48-Week Study Results Showing Viread Comparable to Stavudine in Treatment-Naive HIV Patients
Printer Friendly Version 
April 30, 2002 - 4:26 p.m.
Gilead Sciences Announces First Quarter 2002 Financial Results; Product Revenues Include $27.2 Million in Viread Sales
Printer Friendly Version 
April 29, 2002 - 9:04 a.m.
Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil
Printer Friendly Version 
April 19, 2002 - 8:38 a.m.
Data From Study of Gilead's Adefovir Dipivoxil in Hepatitis B Patients With Lamivudine-Resistant Virus Presented At International Medical Meeting
Printer Friendly Version 
April 18, 2002 - 11:44 a.m.
92-Week Data From Clinical Study of Gilead's Adefovir Dipivoxil in Patients Co-Infected With HIV and Lamivudine-Resistant HBV Presented At International Medical Meeting
Printer Friendly Version 
April 18, 2002 - 11:33 a.m.
Gilead Announces Presentation of Data From Phase III Study of Adefovir Dipivoxil in Patients With Precore Mutant Chronic Hepatitis B
Printer Friendly Version 
April 15, 2002 - 7:14 p.m.
Gilead Sciences to Release First Quarter 2002 Financial Results On Tuesday, April 30, 2002; Conference Call and Webcast to Follow
Printer Friendly Version 
March 29, 2002 - 8:15 p.m.
Gilead Announces Changes to Senior Management Team; Organization Positioned for Continued Growth
Printer Friendly Version 
March 26, 2002 - 8:05 a.m.
Gilead Submits Marketing Authorisation Application for Adefovir Dipivoxil 10 mg for Treatment of Chronic Hepatitis B; EU Application Follows Submission to FDA
Printer Friendly Version 
March 21, 2002 - 4:36 p.m.
Gilead Submits New Drug Application to U.S. FDA for Adefovir Dipivoxil 10 mg for the Treatment of Chronic Hepatitis B
Printer Friendly Version 
March 21, 2002 - 2:58 a.m.
Roche Receives Positive Recommendation in Europe for Tamiflu(R)
Printer Friendly Version 
March 12, 2002 - 8:31 a.m.
Gilead Initiates Early Access Program for Adefovir Dipivoxil, Investigational Treatment for Chronic Hepatitis B Infection
Printer Friendly Version 
February 27, 2002 - 1:59 p.m.
Gilead Announces Data From Study of Viread in Patients Co-infected With HIV and HBV; Data Presented at 9th Conference on Retroviruses and Opportunistic Infections
Printer Friendly Version 
February 25, 2002 - 1:35 p.m.
Viread Demonstrates Anti-HIV Potency Similar to the Protease Inhibitor Ritonavir in Short-Term Study of Treatment-Naive Patients
Printer Friendly Version 
February 25, 2002 - 9:05 a.m.
Gilead Launches Web Site for New Anti-HIV Drug Viread
Printer Friendly Version 
February 25, 2002 - 9:05 a.m.
Gilead Sciences' Viread Suppresses HIV Viral Load Through 48 Weeks in Phase III Clinical Trial
Printer Friendly Version 
February 07, 2002 - 9:58 a.m.
Gilead Sciences' New HIV Drug Viread Approved for Marketing in European Union
Printer Friendly Version 
January 31, 2002 - 4:34 p.m.
Gilead Sciences Announces Fourth Quarter and Year End 2001 Financial Results; Product Revenues Increased 57 Percent Over Fourth Quarter 2000
Printer Friendly Version 
January 30, 2002 - 4:58 p.m.
Gilead Board of Directors Approves Two-for-One Stock Split
Printer Friendly Version 
January 29, 2002 - 6:07 p.m.
Gilead Sciences to Release Fourth Quarter and Year-End 2001 Financial Results On Thursday, January 31, 2002; Conference Call and Webcast to Follow
Printer Friendly Version 
NASDAQ (US Dollar)
$81.21
 Stock is Down 0.38 (0.47%)
Data as of 10/20/17 4:15 p.m. ET
Minimum 20 minute delay
Refresh Quote